In 2023, Teva made a pledge to bolster its innovative medicines portfolio without leaving behind its century-long legacy as a ...

Teva has penned a second pact with Royalty Pharma, this time securing up to $500 million to support the clinical development ...

Key Insights The projected fair value for Teva Pharmaceutical Industries is US$57.59 based on 2 Stage Free Cash Flow ...

Royalty Pharma and the US affiliate of Israel’s Teva Pharmaceutical Industries have announced a funding agreement of up to ...

Teva and Royalty Pharma have signed a deal worth up to $500 million to advance TEV-408, a drug being tested for vitiligo and ...

A class action lawsuit was filed in New York federal court on Friday accusing Novo Nordisk (NVO) of running a "pay-for-delay" ...

Shares of Teva -- a generic-drug maker with a history of losses and high leverage -- have rallied strongly. Pfizer and Merck, which make branded drugs, are financially strong and are rebuilding their ...

Novo Nordisk AS was sued in federal court Friday with allegations that it monopolized the blockbuster weight loss medication Victoza through an illegal deal with a competitor to delay the generic, ...

A federal judge denied Teva's bid to delay the first Paragard bellwether trial, keeping a January start date for claims tied ...